Nardelli Carmela, Aveta Achille, Pandolfo Savio Domenico, Tripodi Lorella, Russo Filippo, Imbimbo Ciro, Castaldo Giuseppe, Pastore Lucio
CEINGE-Biotecnologie Avanzate Franco Salvatore, Naples, Italy.
Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Naples, Italy.
Eur Urol Open Sci. 2023 Dec 19;59:18-26. doi: 10.1016/j.euros.2023.11.003. eCollection 2024 Jan.
Several studies support the interplay between the urinary microbiome (ie, urobiome) and bladder cancer (BCa). Specific urinary bacteria may be responsible for chronic inflammation, which in turn promotes carcinogenesis. Different signatures of urobiome in BCa patients were identified depending on tumor type, geographical area, age, and sex.
We explored the urobiome in BCa patients undergoing transurethral resection of bladder tumor (TURBT), to identify possible predictive biomarkers of cancer.
The urobiome analysis was conducted in 48 patients (13 females) undergoing TURBT, of whom 30 with BCa (five females) and 18 with benign bladder tumor, analyzing bacterial 16S rRNA by next-generation sequencing in first-morning (FM) urine samples. Forty-three cancer-free individuals and 17 prostate cancer patients were used as controls.
First, we identified the better urine collection procedure to perform the urobiome analysis, comparing bacterial composition between catheterized (CAT) and FM urine samples in TURBT patients. Successively, we observed a specific urobiome in BCa patients rather than controls. A combined pipeline including the DESeq2 and linear discriminant analysis effect size tests was used to identify differential urinary taxa, strictly associated with BCa patients.
The bacterial composition of CAT and FM urine samples was comparable, so the latter was used for the following analyses. An increased abundance of and was found in BCa patients compared with controls. This signature seems to be more related ( <0.05) to male BCa patients over 50 yr old. Owing to the low biomass of urinary microbiota, several samples were excluded from the study, reducing the number of BCa patients considered.
FM urine samples represent a manageable specimen for a urobiome analysis; is a specific biomarker of BCa risk.
Our study showed an increased abundance of and in male bladder cancer (BCa) patients, supporting the use of a first-morning urine sample, a less invasive and low-cost collection method, for the urobiome analysis of patients at risk of BCa.
多项研究支持泌尿微生物群(即尿微生物群)与膀胱癌(BCa)之间的相互作用。特定的尿道细菌可能导致慢性炎症,进而促进癌症发生。根据肿瘤类型、地理区域、年龄和性别,已确定BCa患者尿微生物群的不同特征。
我们对接受经尿道膀胱肿瘤切除术(TURBT)的BCa患者的尿微生物群进行了研究,以确定可能的癌症预测生物标志物。
设计、设置和参与者:对48例接受TURBT的患者(13例女性)进行了尿微生物群分析,其中30例为BCa患者(5例女性),18例为良性膀胱肿瘤患者,通过下一代测序分析晨尿(FM)样本中的细菌16S rRNA。43名无癌个体和17名前列腺癌患者作为对照。
首先,我们通过比较TURBT患者导尿(CAT)和FM尿液样本中的细菌组成,确定了进行尿微生物群分析的最佳尿液采集程序。随后,我们观察到BCa患者而非对照组有特定的尿微生物群。使用包括DESeq2和线性判别分析效应大小测试在内的组合流程来识别与BCa患者密切相关的差异尿类群。
CAT和FM尿液样本的细菌组成具有可比性,因此后者用于后续分析。与对照组相比,BCa患者中 和 的丰度增加。这种特征似乎与50岁以上的男性BCa患者更相关( <0.05)。由于尿微生物群的生物量较低,几个样本被排除在研究之外,从而减少了所考虑的BCa患者数量。
FM尿液样本是用于尿微生物群分析的可控样本; 是BCa风险的特定生物标志物。
我们的研究表明,男性膀胱癌(BCa)患者中 和 的丰度增加,支持使用晨尿样本(一种侵入性较小且成本较低的采集方法)对有BCa风险的患者进行尿微生物群分析。